# Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

> **NCT04074746** · PHASE1,PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 45 (actual)

## Conditions studied

- Recurrent Anaplastic Large Cell Lymphoma
- Recurrent B-Cell Non-Hodgkin Lymphoma
- Recurrent Classic Hodgkin Lymphoma
- Recurrent Mycosis Fungoides
- Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Refractory Anaplastic Large Cell Lymphoma
- Refractory B-Cell Non-Hodgkin Lymphoma
- Refractory Classic Hodgkin Lymphoma
- Refractory Mycosis Fungoides
- Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified

## Interventions

- **BIOLOGICAL:** Anti-CD30/CD16A Monoclonal Antibody AFM13
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Fludarabine Phosphate
- **BIOLOGICAL:** Genetically Engineered Lymphocyte Therapy

## Key facts

- **NCT ID:** NCT04074746
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-18
- **Primary completion:** 2025-09-22
- **Final completion:** 2025-09-22
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2025-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04074746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04074746, "Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04074746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*